SURGE Therapeutics

About SURGE Therapeutics

SURGE Therapeutics is an intraoperative immunotherapy company focused on transforming cancer treatment by deploying immunotherapy during surgery to improve survival outcomes. Their mission is to prevent post-surgical recurrence and metastasis in cancer patients undergoing tumor resection through innovative immunotherapy solutions.

Products & Services

Biodegradable Hydrogel for Immunotherapy:A hydrogel injected at the site of surgical tumor resection to extend the release of cancer immunotherapy locally, aiming to trigger the immune system to eliminate remaining cancer cells and prevent recurrence.

Specialties

Intraoperative Immunotherapy Cancer Treatment Biodegradable Hydrogel Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 32000000 MR: - FA: $32 million FAN: 32000000	D: 2023-07-19 FD: 2023-07-19	10 investors

Series B Latest

2023-07-19

$32.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Goldberg

CEO

R

Robert Langer

Institute Professor, MIT

P

Phillip Sharp

Nobel Laureate

C

Charles S. Carignan

CXO

K

Kayti Aviano

VP, Clinical Operations

P

Paul Konowicz

Head of Formulations

View 7 more team members with Pro

Unlock Full Team Directory

Recent News